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Introduction:  Balloon  pulmonary  angioplasty  (BPA)  has  emerged  as  a  promising  therapeutic
option for  patients  with  chronic  thromboembolic  pulmonary  hypertension  (CTEPH)  who  are
not eligible  for  pulmonary  thromboendarterectomy  (PEA)  or  who  have  recurrent  or  persistent
pulmonary  hypertension  after  surgery.  There  is  no  standardized  technique  for  BPA  and,  its
complexity  and  high  risk  of  severe  complications,  requires  skills  and  appropriate  training  and
should be  reserved  for  expert  CTEPH  centers,  as  a  complementary  intervention  to  medical  and
surgical therapy.
Objective:  The  purpose  of  this  document  is  to  describe  the  BPA  protocol  used  at  a  high-volume
center nationwide,  validated  by  its  results.
Methods:  The  present  protocol  includes  technical  details,  definition  of  outcomes  and
complications,  as  well  as  patient  full  diagnostic  work-up  and  treatment  algorithm,  before  and
after BPA.
Results:  The  technical,  hemodynamic,  and  clinical  results  of  the  application  of  this  protocol
will be  subject  of  a  later  publication  where  they  will  be  described  in  detail.  In  conclusion,  we
present a  percutaneous  intervention  protocol  in  the  treatment  of  pulmonary  hypertension  in
the context  of  chronic  pulmonary  thromboembolism,  validated  by  its  clinical,  hemodynamic,
and technical  results.sa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
he  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-©  2021  Sociedade  Portugue
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Protocolo  de  angioplastia  pulmonar  de  balão  num  centro  de  referência  nacional  em
hipertensão  pulmonar
Resumo
Introdução:  A  angioplastia  da  artéria  pulmonar  com  balão  (APB)  é  uma  opção  terapêutica
promissora  para  doentes  com  hipertensão  pulmonar  tromboembólica  crónica  (HPTEC),  não
elegíveis  para  tromboendarterectomia  pulmonar  ou  que  apresentam  hipertensão  pulmonar
recorrente  ou  persistente  após  cirurgia.  Não  existe  uma  técnica  padronizada  para  APB,  a  sua
complexidade  e  seu  elevado  risco  de  complicações  severas  requerem  competências  e  um  treino
apropriado  e  deve  ser  reservada  para  centros  especializados  em  HPTEC  e  como  uma  intervenção
complementar  à  terapêutica  médica  e  cirúrgica.
Objetivo:  Divulgar  um  protocolo  de  APB  usado  num  centro  com  elevado  volume  a  nível  nacional,
validado pelos  seus  resultados.
Métodos:  O  presente  protocolo  inclui  detalhes  técnicos,  definição  atual  de  resultados  e
complicações, bem  como  o  algoritmo  de  avaliação  diagnóstica  e  tratamento  do  doente  antes  e
depois da  APB.
Resultados:  Os  resultados  técnicos,  hemodinâmicos  e  clínicos  da  aplicação  deste  protocolo
serão alvo  de  uma  publicação  posterior,  na  qual  serão  descritos  em  detalhe.
Conclusão:  Apresentamos  um  protocolo  de  intervenção  percutânea  no  tratamento  de  hiperten-
são pulmonar  em  contexto  de  tromboembolismo  pulmonar  crónico,  validado  pelos  seus
resultados  clínicos,  hemodinâmicos  e  técnicos.
© 2021  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um























































ulmonary  hypertension  (PH)  is  a  condition  characterized
y  an  increase  in  pulmonary  artery  pressure  (PAP),  which
an  be  found  in  multiple  clinical  situations.1 Currently,  a
evised  threshold  for  pre-capillary  PH  --  a  combination  of
ean  PAP>20  mmHg,  pulmonary  arterial  wedge  pressure<15
mHg  and  pulmonary  vascular  resistance  (PVR)>3  Wood  unit
-  has  been  proposed  by  the  6th  World  Symposium  on  Pul-
onary  Hypertension.2 Chronic  thromboembolic  pulmonary
ypertension  (CTEPH),  within  group  four  PH,  has  a  cumula-
ive  incidence  reported  between  0.1  and  9.1%  in  the  first
wo  years  after  a  symptomatic  pulmonary  embolism  (PE)
vent.3 Following  persistent  obstruction  of  pulmonary  arter-
es  by  organized  thrombi,  flow  redistribution  and  secondary
emodeling  of  the  pulmonary  microvascular  bed  lead  to
rogressive  increase  in  PVR,  PH  and  right  heart  afterload,
ltimately  progressing  to  right  ventricular  (RV)  failure  and
eath,1,4 if  left  untreated.  CTEPH  is  associated  with  poor
rognosis  when  treated  only  medically.
Pulmonary  thromboendarterectomy  (PEA)  is  the  first-line
reatment.  At  experienced  centers,  it  is  associated  with
n  in-hospital  mortality  rate  below  5%  and  confers  hemo-
ynamic  and  functional  improvement  with  good  long-term
urvival.5 However,  less  than  60%  of  patients  are  eligible  for
urgery.6 For  inoperable  cases,  PH-specific  medical  therapy
ith  soluble  guanylate  cyclase  (sGC)  riociguat,7 in  addition
o  chronic  anticoagulation  therapy,  should  be  the  standard
edical  treatment.  Balloon  pulmonary  angioplasty  (BPA),
ith  sequential  dilation  of  stenotic  or  obstructed  pulmonary
rteries,  appears  as  an  emerging  therapeutic  option  for




65ho  have  recurrent  or  persistent  pulmonary  hypertension
fter  PEA.8 Interventional  BPA  is  already  mentioned  in  the
uropean  guidelines  for  pulmonary  hypertension  for  non-
perable  patients  with  CTEPH  (recommendation  class  IIb,
evel  of  evidence  C).1
Although  there  is  no  standardized  technique  for  BPA,  it
equires  appropriate  training.  Patient  selection  and  mana-
ement  of  complications  remains  a  challenge.  For  these
easons,  BPA  as  a  complementary  intervention  to  medical
nd  surgical  therapy,  should  be  reserved  for  expert  CTEPH
enters,  with  experience  in  the  evaluation  and  care  of  this
nique  patient  population.9
The  purpose  of  the  current  document  is  to  describe  the
PA  protocol  used  in  our  center,  which  includes  procedure
etails,  current  definition  of  outcomes  and  complications,
s  well  as  the  patient  screening  and  treatment  algorithm
efore  and  after  BPA.
valuation before balloon pulmonary
ngioplasty
he  diagnosis  of  CTEPH  is  based  on  findings  obtained  after
hree  months  of  effective  anticoagulation,  to  distinguish  this
ondition  from  acute  PE.
As  recommended  by  the  current  guidelines,1 the  ini-
ial  imaging  test  used  for  CTEPH  screening  in  our  center
s  the  V/Q  scan.  It  has  the  ability  to  exclude  the  disease
ith  a sensitivity  and  specificity  of  90-100%  and  94-100%,
espectively.10
In  a  patient  with  mismatching  perfusion  defects  on
ung  ventilation/perfusion  scintigraphy  (V/Q  scan),3 CTEPH
4
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Table  1  Assessment  at  baseline  and  timing  for  the  follow-up  of  patients  treated  with  balloon  angioplasty  for  chronic  throm-
boembolic pulmonary  hypertension.
At  baseline  3-6  months





After  3  months
of  completed
BPA  procedures
After  6  months
of completed
BPA  procedures
In  case  of
clinical
worsening
Clinic  visit  and
WHO  functional
class




X*1 X  X  X  X  X
Blood gas
analysis




ECG  X  X  X  X  X  X
Echocardiogram  X  X  X  X
6MWT/Borg
dyspnea score
X  X  X  X
CPET X*3 X  X
Right heart
catheterization
X  X  X  X  X
V/Q scan X  X
DSA X  X
CTPA X X
Table adapted from Galiè N, et al.1
BPA: balloon pulmonary angioplasty; BNP: brain natriuretic peptide; CPET: cardiopulmonary exercise testing; CTEPH: chronic throm-
boembolic pulmonary hypertension; CTPA: computed tomography pulmonary angiography; DSA: digital subtraction angiography; V/Q
scan: lung ventilation/perfusion scintigraphy; WHO: World Health Organization; 6MWT: six-minute walking test.
*1 At baseline include thyroid function, viral serologies (hepatitis B and C and human immunodeficiency virus); screening for hypercoag-







































* Including spirometry, lung volumes, diffusion capacity of carbo
*3 For those who can perform a maximal six-minute walking test.
iagnosis  requires  invasive  confirmation  of  PH  through  right
eart  catheterization  (RHC).
Prior  to  the  multidisciplinary  CTEPH  team  meeting,  a
ull  clinical  evaluation  and  investigation  is  required  (see
able  1).
atheter-based pulmonary angiography and
ight heart catheterization
iplanar  digital  subtraction  angiography  (DSA)11 and  electro-
ardiography  (ECG)-gated  computed  tomography  pulmonary
ngiography  (CTPA)12 are  both  used  to  characterize  vessel
orphology,  the  types  of  lesions  (ring-like  stenosis,  web,
ubtotal,  total  occlusions  or  tortuous  lesions  --  Figure  1)
nd  location  of  thrombi  in  the  main,  lobar,  or  segmental
ulmonary  arteries.13 CTPA  gives  us  complementary  infor-
ation  about  the  presence  of  bronchial  collateral  arteries
which  can  correlate  with  more  central  disease14),  lung
arenchyma  and  mediastinum.12
For  biplanar  DSA  (Figure  2),  femoral  vein  access  is  usually
sed,  but  the  jugular  is  also  possible.  A  pigtail  catheter  5
r  6  Fr  is  used  to  perform  angiography.  Low  osmolarity  ion
ontrast  injection,  and  an  automatic  injector,  with  a  volume






everity  of  pulmonary  hypertension),  pressure  limit  of  1000
si  and  injection  delay  of  2  seconds  is  used.  The  acquisition
f  images  should  be  in  apnea,  two  to  three  seconds  after
eep  inspiration,  in  digital  subtraction  angiography  mode,
ix  to  ten  frames/s,  with  the  field  of  view  not  enlarged.
RHC  is  performed  at  baseline  and  repeated  three  to  six
onths  after  change  in  vasodilator  therapy,  before  each  BPA
ession  and  after  six  months  of  BPA  procedures.  Table  2
resents  the  directly  invasive  and  non-invasive  measure-
ents  and  calculated  parameters  obtained  in  RHC  for  these
atients  at  our  institution.15
election of patients for balloon pulmonary
ngioplasty
fter  the  full  diagnostic  work-up  is  complete,  all  cases
re  discussed  in  a  multidisciplinary  CTEPH  team  meeting,
ncluding  surgeons  experienced  in  PEA,  interventional  radi-
logists  or  cardiologists,  expert  radiologists  in  pulmonary
ascular  imaging,  and  clinicians  with  expertise  in  PH,  to
ccess  potential  eligibility  for  surgery.  The  CTEPH  team
onfirms  the  diagnosis,  assesses  the  surgical  accessibility
f  thrombotic  lesions  (surgical  operability),  and  consid-
rs  comorbidities  that  may  increase  surgical  morbidity  and
5
R.  Calé,  F.  Ferreira,  A.R.  Pereira  et  al.
Figure  1  Angiographic  classification  of  CTEPH  lesions.
(A) Type  A:  ring-like  stenosis  lesion.  (B)  Type  B:  web  lesion.  (C)  Type  C:  subtotal  lesion.  (D)  Type  D:  total  occlusion  lesion.  (E)
Type E:  tortuous  lesion.  From  A  to  E  increases  the  complexity  of  BPA;  decreasing  the  success  rate  and  increasing  the  likelihood  of
complications.
Reprinted with  permission  from  Kawakami  et  al.  Circ  Cardiovasc  Interv  2016;9:e003318.
Figure  2  Digital  subtraction  angiography  of  two  BPA  patients  (represented  by  upper  and  lowercase  letters,  respectively).  We
perform selective  angiography  of  the  right  and  left  pulmonary  arteries,  acquiring  images  in  anteroposterior  (A  and  B;  a  and  b)  and
p nt.  D








rofile (C  and  D;  c  and  d)  using  a  biplane  angiography  equipme
rrows), ring-like  stenosis  (blue  arrows)  and  occlusion-type  lesi
ortality  risk  (‘medical  operability’).3 Table  3  lists  anatom-
cal  and  clinical  features  that  can  predict  an  unfavorable
utcome  after  surgery.9BPA  should  be  considered  in  patients  who  are  non-
perable  or  carry  an  unfavorable  risk/benefit  ratio  for  PEA,




65ifferent  types  of  CTEPH  lesions  are  indicated:  web  lesion  (red
urple  arrows).
lso  be  an  alternative  therapy  for  patients  with  persistent
r  recurrent  pulmonary  hypertension  after  PEA.16
Prior  to  any  BPA,  a  patient-based  program  is  tailored.
ll  CTEPH  patients  are  subject  to  clinical  stability  and
ptimal  supportive  treatment  including  appropriate  anti-
oagulant  regimen,  volume  overload  management  with
6
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mRAP  (mmHg)  SBP,  DBP,  MAP
(mmHg)
PVR  (WU)





mPCWP  (mmHg)*1 Weight  (Kg)  SVR  (WU)
CO (L/min)*2 Height  (cm) SVRi  (WU/m2)







BSA: body surface area (Dubois formula); CI: cardiac index; CO:
cardiac output; DBP: diastolic blood pressure; HR: heart rate;
MAP: mean arterial pressure; mRAP: mean right atrial pressure;
sPAP: systolic pulmonary artery pressure; dPAP: diastolic pul-
monary artery pressure; mPAP: mean pulmonary artery pressure;
mPCWP: mean pulmonary capillary wedge pressure; SvO2: mixed
venous oxygen saturation rate.
SBP: systolic blood pressure;
PVR: pulmonary vascular resistance; PVRi: pulmonary vascular
resistance index; SVR: systemic vascular resistance; SVRi: sys-
temic vascular resistance index; SV: stroke volume; Svi: stroke
volume index; WU: Wood Units.
*1 or end-diastolic ventricular pressure when pulmonary capil-























Table  3  Predictable  features  for  risk-benefit  assessment





History  History  of  DVT/PE  No  history  of
DVT/PE
Examination  No  signs  of  right
heart  failure
Signs  of  right
heart  failure
Comorbidity  None  Concomitant  lung




Functional  class  II
or III
Functional  class  IV
Type of  disease  More  proximal
disease
Lower  lobe  disease
More  distal  disease
No  disease  in
lower  lobes
Hemodynamics  PVR<12.5  WU,  in
proportion  to  site
and  number  of
obstructions  in
imaging;  higher  PA
pulse  pressure.
PVR>15  WU,  out  of
proportion  to  site
and  number  of
obstructions  on
imaging;  higher  PA
diastolic  pressure.
Table adapted from Kim et al.4




























* average of three measurements, performed and calculated
using cardiac output device/thermodilution methodology and
indirect Fick method.
udicious  diuretic  use  and  long-term  oxygen  therapy  if
eemed  necessary  to  maintain  PaO2>60  mmHg.1
Specific  targeted  pulmonary  vasodilator  therapy,  includ-
ng  monotherapy  with  the  sGC  stimulator  riociguat  in
ow-risk  patients,  or  add-on  combination  therapy  with  off-
abel  endothelin-receptor  antagonists  and/or  prostanoids  in
igh  risk  patients  is  implemented  and  titrated  in  order  to
ptimize  the  pulmonary  vascular  hemodynamic  profile  prior
o  the  BPA  program.6
A  set  of  clinical  evaluation,  of  each  patient,  are  estab-
ished  at  the  time  of  CTEPH  diagnosis,  before  the  first
aseline  BPA  session,  before  each  subsequent  treatment  ses-
ion  and  three  and  six  months  after  the  last  BPA  session,  as
utlined  in  Table  1.
alloon pulmonary angioplasty technique
he  BPA  technique  used  is  similar  to  others  previously
escribed  in  the  literature.17,18
The  procedure  is  performed  while  maintaining  chronic
utpatient  therapy,  particularly  anticoagulant  therapy
vitamin  K  antagonists  or  direct  oral  anticoagulants)
nd  PH-specific  pulmonary  vasodilators.  The  patient  is
wake,  with  continuous  monitoring  of  oxygen  saturation.
nder  local  anesthesia,  venous  access  is  obtained  in  the





65pulmonary thromboendarterectomy; PVR: pulmonary vascular
resistance.
dministration  of  50  units/kg  of  weight  of  unfractionated
eparin  in  patients  receiving  vitamin  K  antagonists  and
nternational  Normalized  Ratio  (INR)<3.0.  Patients  under
reatment  with  direct  oral  anticoagulant  therapy  receive
000  units  of  unfractionated  heparin  per  hour  of  procedure.
xygen  supplementation  may  be  given  to  ensure  peripheral
xygen  saturation  (SpO2) greater  than  95%.  RHC  is  performed
t  the  beginning  of  each  procedure  for  baseline  hemody-
amic  assessment,  followed  by  selective  catheterization  of
he  right  or  left  pulmonary  artery  and  replacement  of  the
hort  introducer  with  a  6-French  long  sheath  (Flexor  Check-
lo  70  cm,  Cook  Medical  LLC,  IN,  USA;  or  Destination  65  cm,
erumo,  Tokyo,  Japan).
Subsequently,  the  pulmonary  arterial  segment  is
atheterized  using  a  6-French  110-cm  guide  catheter  (Jud-
ins,  Amplatzer  or  Multipurpose,  CardinalHealth,  Dublin,
H,  USA).  Segmental  pulmonary  angiography  is  performed
hile  patients  are  taking  a  deep  breath  and  injection  of
:1  diluted  contrast  at  7.5  to  15  frames/s  without  digital
ubtraction  (Figure  3).
Conventional  angiography  images  are  acquired  from
nteroposterior,  lateral  or  oblique  45◦ views.  Subsequently,
 0.014  guidewire  with  soft,  nontraumatic  tip  is  placed  in
he  distal  vessel.  Most  target  lesions  for  BPA  are  crossed
ith  the  Whisper  MS  wire  (Abbot  Vascular,  Santa  Clara,  CA,
SA)  to  avoid  the  risk  of  vascular  injury  associated  with  the
se  of  polymer-jacketed  guidewires.  For  total  occlusions,
n  antegrade  wire  escalation  supported  by  a  microcatheter
Finecross  130  cm,  Terumo,  Tokyo,  Japan)  and  increasing
uidewire  tip  stiffness  can  be  used  (Pilot  50-150,  Abbot  Vas-
ular,  Santa  Clara,  CA,  USA;  Gaia  First  or  Second  or  Gladius,
sahi  Intecc  Co.,  Aichi,  Japan).  After  crossing  the  target
esion,  we  perform  the  balloon  inflation  of  the  target  lesion
7
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Figure  3  Upper  segment  of  lingula  BPA  (left  lung).  A)  Selective  pulmonary  angiography  showing  total  occlusion  of  one  vessel  in
lingula (red  arrow);  B)  Selective  angiography  of  lingula  and  passage  of  Gladius  guide  wire  (Asahi  Intecc  Co.,  Aichi,  Japan)  through
the vessel;  C)  Vessel  dilation  of  the  occluded  lesion  with  a  3.0/30  mm  semi-compliant  balloon;  D)  Selective  pulmonary  angiography
s revi















































howing a  good  final  result  with  increased  arterial  flow  in  the  p
he distal  wire  with  knuckle-wire  technique  which  gives  securit
ith  2.0  to  9.0  mm  diameter  semi-compliant  coronary  or
eripheral  balloons  depending  on  vessel  diameter  (Trek  or
iatrac  14  Plus,  Abbot  Vascular,  Santa  Clara,  CA,  USA;  Tazuna
r  Ryurei,  Terumo,  Tokyo,  Japan;  Emerge,  Sterling  or  Mus-
ang,  Boston  Scientific,  Marlborough,  MA,  USA;  Pantera  Pro,
iotronik  SE  &  Co  KG,  Berlin,  Germany).
omplementary invasive tools for balloon
ulmonary angioplasty
ontemporary  imaging  modalities,  including  intravascular
ltrasound  (IVUS,  Eagle  Eye  Platinum,  Philips,  North  Ryde,
SW,  Australia;  Figure  4)17 and  optical  coherence  tomogra-
hy  (OCT,  Dragonfly  Optis;  Abbot  Vascular,  Santa  Clara,  CA,
SA;  Figure  5),19,20 have  been  applied  in  BPA  for  a  better
haracterization  of  the  lesion,  its  extension  and  diame-
er.  These  imaging  modalities  are  not  widely  used  as  they
rolong  procedure  time.  Nevertheless,  IVUS  is  particularly
seful  in  determining  the  vessel  diameter  in  total  occlusion
PA  (Figure  4),  increasing  procedure  safety.17 Pressure-wire-
uided  BPA  using  a  microcatheter-based  manometer  (Navvus
apid  exchange  FFR  micro-Catheter,  Acist,  Eden  Prairie,  Min-
esota,  USA)  for  distal  pressure  measurement  can  be  used  to
uide  vessel  dilatation  and  reduce  the  risk  of  lung  injury  in
atients  with  severe  baseline  hemodynamics  (mean  PAP>40
mHg  and/or  PVR>7  WU).21 In  the  severe  patient  subgroup,




65ous  occluded  vessel  (yellow  arrow);  *  shows  the  positioning  of
the  procedure,  decreasing  the  risk  of  perforation.
ean  PAP  (Pd  value)  reaches  20-25  mmHg,1,2 assessed  by
ressure  wire  after  each  dilation  (Figure  6).  In  previous  pub-
ished  data,  the  optimal  cut-off  varies  between  19.5  to  35
mHg.22,23 However,  since  the  mean  PAP  is  normally  <25
mHg,  this  is  the  cut-off  used  by  our  group.  In  some  other
ases,  the  pressure  wire  could  be  useful  to  identify  abnor-
al  lesions  that  are  of  uncertain  significance  when  assessed
y  angiography.  A  Pd/Pa  ratio  of  less  than  0.80  could  be  used
o  guide  treatment.21
election of target lesion and planning of
alloon pulmonary angioplasty procedures
nlike  coronary  revascularization,  clinical  improvement
fter  BPA  is  only  observed  after  sequential  dilation  of
everal  segments  of  the  pulmonary  circulation.  For  this  rea-
on,  successful  treatment  of  BPA  requires  multiple  staged
rocedures  with  repeat  catheterizations  and  dilatation  to
ncrease  the  pulmonary  artery  circuit  cross-sectional  area
nd  total  pulmonary  blood  flow.  In  other  words,  hemody-
amic  improvement  is  usually  not  observed  after  a  single
PA  session;  additional  sessions  are  needed  so  that  clinical
nd  hemodynamic  benefit  can  be  observed.17The  target  lesions  for  each  session  are  selected  by
atching  the  perfusion  defects  on  V/Q  scan,  and  lesion
orphology  in  DSA  and  CTPA  (Figure  7),  which  are  later
onfirmed  through  segmental  pulmonary  angiography.  In  the
8
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Figure  4  Pulmonary  balloon  angioplasty  of  a  total  occluded  vessel  from  a  segment  of  inferior  right  lower  lobe,  guided  by  intravas-
cular ultrasound  (IVUS).  A)  Selective  pulmonary  angiography  showing  occlusion  of  one  of  the  A10  subsegments  (red  arrow);  B  and
C) IVUS  using  an  Eagle  Eye® Platinum  ST  catheter  (Philips,  Amsterdam,  the  Netherlands)  enabling  the  accurate  determination  the
real size  of  the  vessel  and,  thus,  size  the  balloons  to  be  used  during  angioplasty;  D)  Dilatation  of  the  vessel  with  a  4.0-mm  diameter
balloon; E)  Selective  pulmonary  angiography  showing  a  good  final  result  of  chronic  total  occlusion  (CTO)  balloon  plastic  angioplasty
(BPA) (red  arrow).  There  is  another  CTO  in  segment  A9  (yellow  arrow)  that  was  proposed  to  intervene  later;  F)  Two  months  later,
the final  angiography  revealed  good  BPA  result  in  the  previous  CTO  intervention  and  A9  CTO  lesion  successfully  treated.











igure  5  Optical  coherence  tomography.  Intravascular  imagin
essel.
rst  sessions,  the  lobe  with  the  worst  perfusion  is  often  the
arget.  If  there  are  multiple  perfusion  defects,  the  treat-
ent  of  lower  lobe  lesions  where  perfusion  is  greater  and,onsequently,  with  higher  potential  to  reduce  mean  PAP,
re  selected  for  first  BPA  procedures.  The  treatment  of




65hnique  demonstrating  the  presence  of  fibrotic  webs  inside  the
ubtotal  lesions  are  favored.  Total  occlusions  and  tortuous
essel  injuries  are  less  frequently  addressed  during  the  first
essions,  due  to  high  risk  of  vascular  injury.  As  mentioned  by
atsubara  et  al.,24 total  occlusions  although  more  difficult
o  intervene  and  more  likely  to  cause  vascular  injury,  are
lso  related  to  superior  hemodynamic  improvement  when
9
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Figure  6  Pressure-wire-guided  balloon  plastic  angioplasty  of  right  medium  lobe  A5  segment,  measuring  distal  pressure  using  a
microcatheter-based  manometer  (Navvus  rapid  exchange  FFR  micro-Catheter,  Acist,  Eden  Prairie,  Minnesota,  USA).  This  was  the
first session  of  a  severe  chronic  thromboembolic  pulmonary  hypertension  patient  with  systolic  pulmonary  artery  pressure  (PAP)
around 80mmHg  and  mean  PAP  40  to  50  mmHg.  A)  Subocclusion  of  two  A5  subsegments  in  selective  angiography.  Intravascular
hemodynamics  (bottom  left)  revealed  a  significantly  dampened  distal  pressure  waveform  (green  line)  and  resting  Pd/Pa=0.21;  B)



























































ar hemodynamics  (bottom  right)  revealed  improved  distal  pre
ngiographic  result  with  improved  vessel  perfusion  in  both  subs
ompared  to  less  stenotic  lesions.  Increasing  the  number  of
reated  segments,  as  well  as  addressing  difficult  lesions  are
oth  needed  to  improve  the  efficacy  of  BPA.24 Therefore,
he  treatment  of  total  occlusions  can  be  carried  out  in  later
essions,  when  pulmonary  hemodynamics  have  improved.
Pulmonary  flow  grade23 is  estimated  before  and  after
ach  dilation  of  a  treated  segment  or  subsegment  (Table  4).
emi-compliant  balloon  dilation  using  a  relatively  small  bal-
oon  size  is  performed  first  (2.0-mm  balloon),  and  then
alloon  size  is  sequentially  increased  to  obtain  larger  vas-
ular  diameter  and  increased  pulmonary  flow  in  the  target
essel.  The  most  important  when  performing  BPA  is  not  so
uch  the  morphological  result  in  the  dilated  area  as  the
emodynamic  result  (whether  visually  assessed  on  the  qual-
ty  of  the  antegrade  flow  and  venous  return  or  by  measuring
ressures  downstream  of  the  dilated  area).
Due  to  recognized  correlation  between  pre-BPA  mean  PAP
ver  40  mmHg25 and  the  severity  of  reperfusion  lung  injury,
dequate  balloon  sizing  depends  on  hemodynamics,  angio-
raphic  lesion  type  and  estimated  vessel  diameter  (derived
rom  eyeballing  subjective  analysis  of  angiogram  in  most
f  the  lesions)  (Table  5).26 Under  sizing  balloon  to  vessel
iameter  (i.e.  a  low  balloon/vessel  ratio)  is  needed  more
n  patients  with  severe  hemodynamics  (mean  PAP>40  mmHg
nd/or  PVR>7  WU),  especially  in  the  first  sessions.  The  bal-
oon  is  inflated  until  the  fluoroscopic  waist  disappears  or
ntil  5  to  8  atmospheres  is  reached.  The  aim  for  each  target
esion  should  be  the  presence  of  grade  3  final  flow  according
o  the  Pulmonary  Flow  Grade  (Figure  3).  Lesions  with  resid-
al  stenosis  (pulmonary  flow  grade  <3)  can  be  re-intervened
n  subsequent  sessions  with  balloons  of  appropriate  diam-
ter  to  the  vessel  size.  The  total  number  of  segments





66 waveform  with  a  Pd  value  of  22mmHg  (green  line);  C)  Final
nts.
emodynamic  severity,  procedure  time,  and  the  amount  of
odinated  contrast  used.  If  the  patient’s  hemodynamics  are
evere,  preferably  only  two  segments  on  the  same  side  are
reated,  avoiding  intervention  on  both  the  right  and  left
ulmonary  arteries  in  the  same  procedure,  to  restrict  the
reatment  area  at  risk.  If  pre-procedural  pulmonary  hemo-
ynamics  is  not  severe,  there  are  no  limitations  on  the
umber  of  segments  or  lobes  targeted  in  one  session.  Nev-
rtheless,  any  single  BPA  session  should  be  limited  to  <2  Gy
f  radiation  exposure,  60  minutes  of  fluoroscopy  and  maxi-
al  load  of  administered  contrast  adjusted  to  renal  function
<300  ml).
As  multiple  procedures  are  required  to  finalize  the  BPA
rogram,  in  order  to  decrease  the  total  number  of  patient
dmissions,  two  BPA  sessions  are  performed  two  to  four  days
part  at  each  hospital  admission.  RHC  is  repeated  three  to
our  weeks  after  each  BPA  session.  Additional  BPA  sessions
re  performed  until  PVR  and/or  mean  PAP  drops  below  4
U  and  25  mmHg,  respectively,  under  pulmonary  vasodilator
herapy,  and/or  all  accessible  lesions  are  intervened.
efinition of balloon pulmonary
ngioplasty-related  complications
n  an  attempt  to  standardize  reports  of  BPA  complications
t  various  centers,  a  classification  of  complications  was
roposed  by  the  task  force  on  CTEPH  at  the  6th World
ymposium  on  Pulmonary  Hypertension,  and  was  published
ecently  (Table  6).9 The  most  common  complication  of  BPA
s  lung  injury,  characterized  by  lung  opacities  on  chest
adiograph  or  CTPA.  Initially,  it  was  thought  that  the  mech-
nism  was  similar  to  the  reperfusion  edema  that  can  occur
0
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Figure  7  Electrocardiogram-gated  pulmonary  computed  tomography  (CT)  angiography  of  patients  with  chronic  thromboembolic
pulmonary hypertension.  Upper  panel:  A)  and  B)  axial  images  showing  hypodense  linear  structures  forming  webs  and  bands,  inside
the lumen  of  arteries,  consistent  with  residual  thrombus;  C)  demonstrates  luminal  opacities  and  marked  caliber  reduction  of  seg-
mental vessels,  suggesting  subtotal  lesion,  as  well  as  marked  stenosis  of  more  distal,  subsegmental  vessels  (arrowhead).
Middle panel:  D)  Pulmonary  CT  angiography  depicting  right  atrial  dilation  (arrowheads)  and  leftward  deviation  of  the  interventric-
ular septum  (short  arrow)  yielding  a  ‘‘D-shaped’’  left  ventricle.  D  and  E)  right  ventricular  dilation  and  hypertrophy  (long  arrows









ower panel:  F  and  G)  Mosaic  pattern  of  lung  attenuation.  The  
eads) than  adjacent  normal  perfused  lung  (arrows).
fter  PEA.  However,  after  carefully  reviewing  CTPA  images,
jiri  K.  et  al.25 found  that  the  so-called  ‘‘reperfusion  pul-
onary  edema’’  was  a  focal  opacification  located  only
t  the  site  of  BPA-targeted  lesions.  And  for  that  rea-





66perfused  (oligemic)  lung  appears  lower  in  attenuation  (arrow-
ung  injury  is  hemorrhage  caused  by  iatrogenic  vascular
njury  due  to  trauma  caused  by  the  guidewire,  balloon
verdilation  or  high-pressure  contrast  injection.25 The  lung
njury  can  be  classified  according  to  five  degrees  using  a
lassification  system  previously  published  in  the  literature
1
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Table  4  Pulmonary  flow  grade  score.
Grade  0  No  perfusion  or  penetration  with  minimal
perfusion  of  pulmonary  arteries
Grade  1  Partial  perfusion  of  pulmonary  arteries  and  no
perfusion  or  penetration  with  minimal
perfusion  of  pulmonary  veins
Grade  2  Complete  perfusion  of  pulmonary  arteries  and
partial  perfusion  of  pulmonary  veins
Grade 3  Complete  perfusion  of  both  pulmonary  arteries
and veins
Information from Inami et al.24
Table  5  Balloon  sizing  according  to  hemodynamics  severity
and type  of  lesion.











Web 0.8  0.6
Total occlusion  0.6  0.5
Table adapted from Ahn et al.27
mPAP: mean pulmonary artery pressure; PVR: pulmonary vascu-
lar resistance.
Table  6  Balloon  pulmonary  angioplasty  complications.





Allergic  reaction  to
contrast


























Table  7  Classification  of  lung  injury.
Grade  Definition  Oxygen  needs
1  No  significant
recognition  of  lung
injury  on  chest  x-ray,
only  detected  by  CTPA
No  need
2 Mild  small  lung  injury  on
chest  x-ray
Increase  in  oxygen
achievable  with  nasal
cannula  (maximum
4l/min)
3 Moderate  lung  injury  on
chest  x-ray
Elevated  concentration
of  oxygen  with  need  of
facial  mask
4 Moderate  to  severe  lung
injury  on  chest  x-ray
Non-invasive  positive
pressure  ventilation  with
high-concentration
oxygen  inhalation

































Table adapted from Kimet al.9
Table  7).23 An  angiographic  vascular  injury  (perforation)
s  usually  detected  by  the  following  signs:  extravasation
f  contrast,  hypoxemia,  cough,  tachycardia  or  increased
ulmonary  arterial  pressure.  Other  complications  related
o  BPA  were  the  vascular  dissection,  vascular  access  site
omplications  and  contrast  nephropathy  defined  as  a  25%
r  0.5  mg/dl  increase  compared  to  the  pre-procedure  crea-
inine  value.27 Major  complications  related  to  the  procedure
re  moderate  and  severe  lung  injury  (Table  7)  or  other
omplications  that  require  bail-out  intervention,  noninva-
ive  positive-pressure  ventilation,  mechanical  ventilation,
xtracorporeal  membrane  oxygenation,  urgent  surgery  or
eath.Besides  being  aware  of  potential  BPA  complications,
ne  must  learn  how  to  prevent  and  treat  them.  Before
tarting  a  procedure,  the  operator  should  confirm  that  all




66Table adapted from Inami, et al. article.24
CTPA: computed tomography pulmonary angiography.
erious  complication,  pulmonary  artery  perforation,  are
eadily  available  for  use.  Some  measures  that  can  decrease
he  risk  of  pulmonary  perforation  are  careful  wire  posi-
ioning;  using  workhorse  guidewires  with  soft,  nontraumatic
ips,  whenever  possible;  cautious  use  of  polymer-jacketed
uidewires;  using  the  knuckle-wire  technique  (*  in  Figure  3);
ppropriate  balloon  sizing  and  avoiding  the  treatment  of
otal  occlusions  with  no  visible  runoff.  If  a  perforation  or
upture  occurs,  immediate  balloon  tamponade  of  the  vessel
hould  be  performed.  Other  bailout  techniques  are  cov-
red  stent  implantation,  bioabsorbable  gelatin  injection
r  coil  embolization.  In  severe  forms  of  lung  or  vascular
njury,  noninvasive  positive-pressure  ventilation  with  sup-
lemental  oxygen,  mechanical  ventilation  or  extracorporeal
embrane  oxygenation  may  be  needed.9,28
efinition of clinical outcomes of balloon
ulmonary angioplasty
o  date,  there  is  no  standardized  definition  of  short  or  long-
erm  clinical  outcomes  in  literature.
Technical  success  for  each  lesion  is  a  successful  delivery
nd  balloon  expansion  at  the  intended  target  lesion,  and  an
ncrease  of  >1  grade  in  pulmonary  flow  grade  score,  which
epresents  the  increase  in  the  perfusion  of  pulmonary  arter-
es  (Table  4).  The  end  point  for  each  target  lesion  should  be
 pulmonary  flow  grade  of  3.
The  acute  procedural  success  of  each  BPA  session  must
eet  the  angiographic  criterion  of  technical  success  for
t  least  two  targeted  lesions  plus  absence  of  severe
omplications  (requiring  mechanical  ventilation,  extracor-
oreal  membrane  oxygenation  or  urgent  surgery)  and
urvival  at  hospital  discharge.Clinical  success  of  BPA  should  be  evaluated  after  six
onths  of  the  BPA  program  have  been  completed.  The  first
oal  of  a  BPA  process  is  the  relief  of  PH,  invasively  mea-
ured,  with  a  decrease  in  mean  PAP  and  PVR  (to  reach
2
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Table  8  Definition  of  clinical  outcomes  of  balloon  pul-
monary  angioplasty.
Definition  of  technical  success
Technical  success  of  each  lesion  is  defined  by  all  of  the
following  conditions:
-  successful  delivery  and  balloon  expansion  at  the  intended
target  lesion
- increase  of  >1  grade  in  pulmonary  flow  grade  score
Definition  of  procedure  success
Procedure  success  is  defined  by  all  of  the  following
conditions:
- angiographic  criterion  of  technical  success*1
-  absence  of  severe  complications  during  the  hospital  stay*2
-  survival  at  hospital  discharged
Definition  of  clinical  success*3
Primary  outcome  measures:
- To  reach  PVR<4  WU
-  To  reach  mPAP<25  mmHg
Secondary  outcome  measures:
- Change  from  baseline  in  WHO  functional  class
- Change  from  baseline  in  6MWD
- RV  reverse  remodeling  and  change  from  baseline  in  RV
systolic  function
-  Change  from  baseline  in  NT-proBNP  or  BNP
- Change  from  baseline  in  the  number  and  doses  of
vasodilator  therapy
- Withdrawal  of  long-term  oxygen  therapy
BNP: brain natriuretic peptide; mPAP: mean pulmonary artery
pressure; PVR: pulmonary vascular resistance; RV: right ventri-
cle; WHO: World Health Organization; 6MWT: six-minute walking
test.
*1 of at least two targeted lesions.
*2 severe lung injury (as described in Table 7) requiring mechani-
cal ventilation, extracorporeal membrane oxygenation or urgent
surgery.





































































of  pulmonary  vasodilator  therapy  can  be  cautiously  under-
taken  based  on  expert  opinion  followed  by  close  follow-up.alues  below  25  mmHg  and  4WU,  respectively).8,17,18 The
econd  goal  is  an  improvement  of:  a)  clinical  parame-
ers:  exercise  tolerance,  assessed  through  improvement
n  WHO  functional  class,  6-minute  walking  test  (6MWT)
nd/or  cardiopulmonary  exercise  testing;  (CPET)8,17,18 and;
)  right  heart  overload  parameters:  right  ventricular  reverse
emodeling,29 improvement  of  right  ventricular  systolic
unction30 and  decreased  levels  of  N-terminal  pro-B-type
atriuretic  peptide  (NT  pro-BNP).31 In  addition  to  relief  of
H  and  symptoms,  an  important  aim  of  the  BPA  program  is
he  reduction  in  chronic  targeted  vasodilator  therapy  (espe-
ially  prostanoids)  and  the  withdrawal  of  long-term  oxygen
herapy.32 Table  8  summarizes  the  definitions  of  clinical  out-
omes  of  BPA,  proposed  by  our  group.
The  main  long-term  treatment  goal  is  to  decrease  mor-
ality  risk.  Data  from  a  multicenter  registry  from  Japan
eported  a  three-year  survival  rate  of  94.5%  in  308  inop-
rable  CTEPH  patients  treated  with  BPA  (from  2004  to  2016;
408  procedures),8 which  is  higher  when  compared  to  the
oor  prognosis  of  patients  treated  only  medically  (3-year
urvival  rate  described  as  78.4%).33
A
r
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valuation after balloon pulmonary
ngioplasty
ur  protocol  comprises  three  phases  of  post-procedure
ollow-up:  Immediate  post-procedure  care  (0-24  hours),
ost-procedure  care  (24-72  hours)  and  outpatient  clinical
ollow-up,  with  specific  care  at  each  stage,  as  described
elow:
mmediate  post-procedure  care  (0-24  hours)
n  the  first  24  hours  after  the  procedure,  the  patient  must
e  admitted  to  an  intermediate  care  unit  bed  or  equivalent,
apable  of  continuous  electrocardiographic  monitoring  and
ulse  oximetry.  Chest  X-ray  is  requested  in  all  patients.  If
pacification  is  visible  on  the  chest  X-ray,  high-resolution
hest  computed  tomography  without  contrast  is  performed
or  early  detection  of  lung  injury.
Oxygen  therapy  is  provided  if  oxygen  saturation  (SpO2)  is
elow  92%  or  partial  pressure  of  oxygen  (PaO2)  is  below  60
mHg,  delivered  through  nasal  cannula  or  face  mask  up  to
00%  fraction  of  inspired  oxygen,  to  guarantee  SpO2 greater
han  95%.  Non-invasive  ventilation  is  implemented  if  there
s  signs  of  respiratory  distress  and/or  respiratory  failure
espite  O2 supplementation  (respiratory  rate>25  cycles/min
r  SpO2≤92%),  in  the  bilevel  mode  with  a  minimum  expira-
ory  pressure  of  5mmHg  (can  be  increased  to  8  mmHg  if  there
s  no  right  ventricular  failure)  and  target  tidal  volume  of  4-8
l/kg  of  ideal  weight.
During  hospital  stay,  patients  keep  their  previously
rescribed  specific  pulmonary  vasodilators  and  supportive
herapy,  including  oral  anticoagulant  therapy.
ost-procedure  care  (24-72  hours)
hest  X-ray,  laboratory  tests  (which  include  renal  function)
nd  arterial  blood  gas  are  repeated  every  24  hours.  If  there
re  no  complications,  clinical  discharge  is  scheduled  at  48-72
ours,  depending  on  the  patient’s  hemodynamic  profile.
utpatient  clinical  follow-up
fter  completing  the  BPA  process,  all  patients  are  asked  to
ontact  our  PH  center  if  any  deterioration  in  clinical  status
s  perceived.  The  first  reassessment  appointment  is  sched-
led  three  months  after  conclusion  of  the  BPA  program,
hen  patients  are  evaluated  by  PH  expert  physicians.  Clini-
al  assessment  at  this  time  includes  evaluation  of  functional
apacity,  blood  analysis  including  NT  pro-BNP  and  12-lead
lectrocardiogram.  Six  months  after  the  last  BPA  session,
eassessment  includes  all  the  above  and  Doppler  echocar-
iography,  6MWT  or  CPET  and  RHC.  Pulmonary  vasodilator
herapy  is  maintained  from  the  moment  of  inclusion  in
he  BPA  program  until  the  6-month  follow-up  assessment.
fter  this  period,  if  risk  stratification  is  low  with  achieve-
ent  of  normal  or  near-normal  hemodynamics,  weaningnticoagulation  is  provided  lifelong  for  preventing  recur-
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xygen  therapy  is  reassessed  every  BPA  session  with  blood
as  analysis  and  can  be  withdrawn  if  PaO2>60  mmHg  without
xygen  supplementation.
Lifelong  follow-up  is  warranted  to  all  patients  included
n  our  BPA  program.
The  clinical  evaluation  and  exams  for  the  evaluation  at  3
nd  6  months  are  presented  in  Table  1.
inal comments
 successful  BPA  program  requires  extensive  training  and
hould  be  reserved  for  expert  centers.  As  Brenot  et  al.18
emonstrated  in  their  experience,  there  is  a  learning  curve,
ven  after  the  technical  refinements  introduced  by  the
apanese  experience.17 Thus,  programs  must  be  started  with
 proctor  with  recognized  expertise  in  the  technique  and
ppropriate  training  standards.  In  addition,  correct  diag-
ostic  assessment,  management  of  vasodilator  therapy  and
lobal  clinical  care,  before  and  after  the  BPA,  is  one  of  the
illars  dictating  the  success  of  the  technique  in  this  complex
nd  unique  patient  population.  For  these  reasons,  this  pro-
edure  should  be  performed  at  centers  with  expert  CTEPH
eams.  These  multidisciplinary  teams  should  be  capable  of
roviding  all  current  treatment  modalities,  and  for  that,  be
losely  linked  to  a  surgical  center  with  experience  in  PEA
hat  can  determine  the  operability  of  each  patient.34
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